Adma Biologics | ADMA - Cash And Equivalent


Adma Biologics reported $87.63M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Adma Biologics USD 87.63M 26.24M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
BioCryst Pharmaceuticals USD 335.91M 251.83M Dec/2025
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Novavax USD 240.63M 27.39M Dec/2025
Omeros USD 1.9M 2.36M Jun/2025
Takeda JPY 654.94B 26.55B Dec/2025